Table 1.

Key design features of the seven studies included in this integrated analysis

Reference	n, Travoprost 0.004% arm(s) ITT/PP	Study eye IOP criteria	Visits and time points
Netland et al29	197/187	24–36 mmHg at 0800 and 21–36 mmHg at 1000 and 1600 on two separate visits	0800, 1000, and 1600 at baseline, week 2, and week 12
Gross et al27	52/52 Travoprost 54/54 Travoprost with sofZia®	24–36 mmHg at 0800	0800 at baseline and week 2
Lewis et al28	341/339 Travoprost 338/322 Travoprost with sofZia®	24–36 mmHg at 0800 and 21–36 mmHg at 1000 and 1600 on two separate visits	0800, 1000, and 1600 at baseline, week 2, and week 12
Goldberg et al26	197/176	24–36 mmHg at 0900 and 21–36 mmHg at 1100 and 1600 on two separate visits	0900, 1100, and 1600 at baseline, week 2, and week 12
Barnebey et al23	84/77	≥26 mmHg at 0800 on two separate visits, ≥24 mmHg at 1000 on one visit, and ≥22 mmHg at 1600 on one visit	0800, 1000, and 1600 at baseline, week 2, and week 12
Fellman et al24	197/179	24–36 mmHg at 0800 on 2 separate visits	0800, 1000 and 1600 at baseline, week 2 and week 12
Gandolfi et al25	185/177 Travoprost 185/176 Travoprost with sofZia®	24–36 mmHg at 0900 and 21–36 at 1100 and 1600 on two separate visits	0900, 1100 and 1600 at baseline, week 2 and week 12

Abbreviations: ITT, intent to treat; PP, per protocol; IOP, intraocular pressure.